ReWalk 7 Personal Exoskeleton

Overview

ReWalk 7 is the seventh generation of the exoskeleton that pioneered personal use, from the company formerly called ReWalk Robotics and renamed Lifeward in 2024. The FDA cleared it on 2025-03-13, US sales began on 2025-04-15, and it earned a CE mark on 2025-09-08, with Europe (mainly Germany through Lifeward GmbH, under supply contracts with insurers such as BARMER) making up about 40% of sales. It is indicated for spinal cord injury at T7–L5 for home and community use with a certified companion, and T4–T6 inside rehabilitation institutions, and buyers must complete Lifeward's assessment and training certification. The stairs-and-curbs capability, first cleared on the 6.0 in 2023, sets it apart from the Indego Personal, while Wandercraft's Eve goes further by balancing without crutches. Medicare has covered personal exoskeletons as a brace benefit since 2024-01-01, the first major US commercial insurer approved a ReWalk 7 purchase in April 2025, and by February 2026 Aetna, UnitedHealthcare and Humana Medicare Advantage plans had all paid for one. A reported Ottobock Care pilot across about 50 US clinics from August 2026 is (unconfirmed). Published specs for the 7 remain thin, with no weight or battery figures on the official page.